Last Update 24 Jun 26
Fair value Decreased 1.13%BEI: Brand Execution And Q2 Delivery Will Support Recovery Outlook
The analyst price target for Beiersdorf has been reduced by €1 to reflect a lower fair value estimate of €87.37, as analysts factor in a series of recent target cuts and rating downgrades across the Street.
Analyst Commentary
Recent Street research on Beiersdorf points to a mixed but generally cautious stance, with several firms trimming price targets and a few shifting ratings. Together, these changes frame how analysts are thinking about the stock's valuation, execution risk and potential growth path.
Bullish Takeaways
- Bullish analysts highlight that at least one recent upgrade suggests room for Beiersdorf shares to perform in line with, or better than, previous expectations if execution improves.
- Supportive views often point to the current share price sitting closer to reduced targets, which some see as limiting downside if the company delivers against upcoming milestones such as Q2 results on August 5.
- The maintenance of Neutral and Hold ratings alongside lower targets, including at JPMorgan, signals that some analysts still see Beiersdorf as reasonably valued rather than structurally impaired.
- For investors, this mix of an upgrade and several Neutral stances can indicate that Beiersdorf may appeal to those looking for steadier exposure, provided they are comfortable with moderate return expectations.
Bearish Takeaways
- Bearish analysts have cut price targets across a range of firms, including a move from €90 to €80 at JPMorgan, which points to lower assessed fair value for Beiersdorf relative to earlier assumptions.
- The downgrade to Equal Weight from Overweight, with the price target reduced to €76 from €82, reflects concern that Beiersdorf's newer product initiatives, which are described as moving away from being strongly science based, may not be enough to materially lift revenue growth.
- Several smaller reductions in targets, including cuts of €25, €4 and €2, suggest a cautious stance on Beiersdorf's ability to fully deliver on prior growth expectations or margin execution.
- The downgrade at Goldman Sachs, alongside other target cuts, reinforces the idea that a number of analysts view the risk or reward balance as less attractive than before, which may weigh on sentiment until there is clearer evidence on execution and growth drivers.
What’s in the News for Beiersdorf
- No recent Beiersdorf specific news items or key developments were provided in the available sources.
- Analyst commentary currently centers on revised price targets and rating changes, with no additional company disclosures cited in the supplied material.
- Investors following Beiersdorf may need to rely on upcoming scheduled events, such as the Q2 results on August 5, for fresh company information beyond the analyst target revisions already discussed.
Valuation Changes for Beiersdorf
- Fair Value, revised slightly lower to €87.37 from €88.37, reflects a modest adjustment in the stock's assessed worth.
- Discount Rate, nudged up from 5.44% to 5.46%, indicating a small change in the required return used in Beiersdorf's valuation.
- Revenue Growth, now set at 2.01% from 2.05%, signals a slightly more conservative view on future euro revenue expansion.
- Net Profit Margin, trimmed marginally to 9.76% from 9.81%, points to a small adjustment in expected profitability on euro earnings.
- Future P/E, eased to 21.08x from 21.18x, suggesting a minor recalibration in how Beiersdorf's forward earnings are being valued.
Key Takeaways
- Science-driven product innovation and premiumization are boosting brand equity and enabling profitable growth in both premium and mass-market skincare segments.
- Expansion in emerging markets and advances in digital transformation are increasing market reach and supporting sustainable revenue and margin improvements.
- Increased competition, market uncertainty, retailer pressures, and rising costs are constraining Beiersdorf's growth, pricing power, and profitability across core and premium segments.
Catalysts
About Beiersdorf- Manufactures and distributes consumer goods in Europe, the United States, Africa, Asia, and Australia.
- Breakthrough innovation in science-based skincare, particularly the global rollout of the Epicelline anti-aging ingredient under both Eucerin and NIVEA, positions Beiersdorf to capture increased demand from an aging, health-conscious population, driving higher-margin revenue growth from both premium and mass-market channels.
- Strategic expansion in emerging markets-illustrated by Eucerin's successful entry and strong growth in China and India-capitalizes on rising middle class purchasing power and urbanization, expanding Beiersdorf's addressable market and providing a runway for sustained organic revenue growth.
- Aggressive pivot towards premiumization and premium science-backed offerings (e.g., NIVEA Epigenetics Serum, Derma Control deodorant, Thiamidol range) enables higher average selling prices, improved consumer repurchase rates, and supports gross margin expansion over the long term.
- Accelerating digital transformation in marketing, distribution, and direct-to-consumer approaches, especially in China and across e-commerce, is enhancing brand equity, increasing ROI on marketing spend, and supporting both top-line growth and operating leverage.
- Recent resolution of retailer delistings and pricing negotiations in Europe, combined with a robust innovation/launch pipeline in H2 and broader geographic relistings, is expected to yield a rebound in sales volumes and positively impact near-term revenue and profit margins.
Beiersdorf Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Beiersdorf's revenue will grow by 2.0% annually over the next 3 years.
- Analysts assume that profit margins will increase from 9.5% today to 9.8% in 3 years time.
- Analysts expect earnings to reach €1.0 billion (and earnings per share of €4.88) by about June 2029, up from €939.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting €1.2 billion in earnings, and the most bearish expecting €901.4 million.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 21.1x on those 2029 earnings, up from 16.6x today. This future PE is greater than the current PE for the GB Personal Products industry at 16.6x.
- Analysts expect the number of shares outstanding to decline by 1.29% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 5.46%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Intensifying competition from local brands and private labels, particularly in emerging markets and mass market segments, is eroding NIVEA's volume growth and market share, which could lead to lower revenues and compressed pricing power over the long term.
- Weaker-than-anticipated market growth in key regions (notably emerging markets and Eastern Europe), combined with volatile demand and consumer caution, is slowing Beiersdorf's top-line organic growth and undermining long-term revenue expansion.
- Persistent retailer pressure in Europe-evidenced by delistings, heightened demands for price reductions, and delayed relistings-suggests that Beiersdorf's pricing strategies may negatively affect shelf presence and sales volumes, risking downward pressure on revenue and net margins if retailer relations do not stabilize.
- Ongoing underperformance in the luxury La Prairie segment and slow progress in building scale for premium brands in the US and travel retail reduce anticipated margin expansion and leave Beiersdorf vulnerable to market headwinds in high-margin categories, dragging on overall group profitability.
- Rising costs due to innovation-driven marketing investments, the need to overinvest in digitalization and e-commerce, ongoing regulatory changes (such as US/Swiss tariffs), and unfavorable foreign exchange effects are collectively raising the cost base faster than sales growth, resulting in only modest---or flat---net earnings and jeopardizing margin improvement in the medium to long term.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of €87.37 for Beiersdorf based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €110.0, and the most bearish reporting a price target of just €68.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €10.5 billion, earnings will come to €1.0 billion, and it would be trading on a PE ratio of 21.1x, assuming you use a discount rate of 5.5%.
- Given the current share price of €71.26, the analyst price target of €87.37 is 18.4% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Beiersdorf?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.